Literature DB >> 32736812

Pregnancy with multiple sclerosis.

S Vukusic1, L Michel2, S Leguy3, C Lebrun-Frenay4.   

Abstract

Multiple sclerosis (MS) is usually diagnosed between twenty and forty years of age, when people often plan to have children. A lot has been said about the effect of pregnancy on the course of MS. The individual factors responsible for the disease modifying effect of pregnancy are not well determined. Having MS neither affects the fertility or the course of pregnancy itself. During pregnancy, many women find that their symptoms stay the same or even improve. Epidural and spinal analgesia appear to be safe and in general are not contraindicated for patients with MS. The management of disease-modifying treatments (DMTs) in pregnancy is a new issue for consideration in the clinical practice. There is limited information available into the safety of DMT use during pregnancy, especially for the most recent ones. In general, discontinuation of DMTs is recommended before conception to minimize risk of fetal harm. Women with very active MS before pregnancy who stop second-line treatments may show an increase in disease activity during pregnancy. Therefore, it might be discussed to maintain patients on DMTs until pregnancy is confirmed, and sometimes throughout pregnancy, to avoid a rebound of disease activity and severe relapses during pregnancy in very active patients.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Breastfeeding; Delivery; Disease modifying drugs; Multiple sclerosis; Pregnancy

Mesh:

Year:  2020        PMID: 32736812     DOI: 10.1016/j.neurol.2020.05.005

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  4 in total

Review 1.  Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review.

Authors:  Fioravante Capone; Angela Albanese; Giorgia Quadri; Vincenzo Di Lazzaro; Emma Falato; Antonio Cortese; Laura De Giglio; Elisabetta Ferraro
Journal:  Front Neurol       Date:  2022-04-15       Impact factor: 4.003

2.  Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis - COBRA study.

Authors:  Andrea Ines Ciplea; Anna Kurzeja; Sandra Thiel; Sabrina Haben; Jessica Alexander; Evelyn Adamus; Kerstin Hellwig
Journal:  Mult Scler       Date:  2022-04-01       Impact factor: 5.855

3.  The Rate of Hospitalization of Pregnant Women with Multiple Sclerosis in Poland.

Authors:  Dorota Walkiewicz; Bożena Adamczyk; Michał Maluchnik; Jakub Perwieniec; Krzysztof Podwójcic; Mateusz Szeląg; Michał Zakrzewski; Konrad Rejdak; Agnieszka Słowik; Marcin Wnuk; Monika Adamczyk-Sowa
Journal:  J Clin Med       Date:  2022-09-23       Impact factor: 4.964

Review 4.  Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.

Authors:  Isabella Laura Simone; Carla Tortorella; Alma Ghirelli
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.